SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus Network

Aventus Network (AVT) is trending as the community highlights its recent move to decentralize governance via the Aventus DAO in the UAE and the appointment of strategic leadership to drive enterprise adoption. Investors are buzzing about the project's Polkadot-integrated infrastructure and the potential for a breakout, though many are closely monitoring trading volume to see if it can sustain a move past current resistance levels.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor is gaining momentum as investors draw parallels between its tokenomics and Bitcoin, highlighting its fixed 21 million supply cap and an upcoming halving event as key catalysts for scarcity. The community is actively discussing the platform's role in decentralized AI infrastructure, with many traders framing it as a long-term play while tracking institutional interest and the growth of its subnet ecosystem.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

MSTY is trending as investors debate the impact of an upcoming 1-for-5 reverse stock split amidst ongoing volatility in its underlying asset, MicroStrategy. Community discussion remains polarized, with some traders leveraging the fund for aggressive weekly income strategies, while many others are expressing frustration over consistent NAV erosion and the declining value of distributions.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

The Pyth Network is gaining significant community attention as a leader in the real-world asset (RWA) and oracle sectors, fueled by its ongoing token buyback program and institutional partnerships with government entities. Investors are actively discussing its fundamental utility and competitive position against meme coins, viewing the network's high-fidelity data feeds as essential infrastructure for the next cycle of decentralized finance growth.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as investors debate its potential for a supply-driven breakout, with many citing its status as a mature proof-of-work asset as a long-term advantage. While some in the community express frustration over recent underperformance and lack of retail volume, others are actively accumulating during current consolidation, pinning their hopes on regulatory developments and institutional adoption.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as the community debates its valuation following significant analyst upgrades and growing speculation regarding potential acquisition activity. Investors are actively discussing the company's turnaround progress under new leadership and its role in the shifting digital health landscape.

Blackstone, Inc. engages in the provision of investment and fund management services. It operates through the following segments: Real Estate, Private Equity, Credit and Insurance, and Hedge Fund Solutions. The Real Estate segment includes management of opportunistic real estate funds, Core+ real estate funds, high-yield real estate debt funds, and liquid real estate debt funds. The Private Equity segment consists of management of flagship corporate private equity funds, sector and geographically focused corporate private equity funds, core private equity funds, an opportunistic investment platform, a secondary fund of funds business, infrastructure-focused funds, a life sciences investment platform, a growth equity investment platform, a multi-asset investment program for eligible high net worth investors and a capital markets services business. The Credit and Insurance segment refers to Blackstone Credit, which is organized into two overarching strategies: private credit which includes mezzanine direct lending funds, private placement strategies, stressed and distressed strategies and energy strategies, and liquid credit which consists of CLOs, closed-ended funds, open ended funds and separately managed accounts. In addition, the segment includes an insurer-focused platform, an asset-based finance platform, and publicly traded master limited partnership investment platform. The Hedge Fund Solutions segment focuses on Blackstone Alternative Asset Management, which manages a broad range of commingled and customized hedge fund of fund solutions. It also includes a GP Stakes business and investment platforms that invest directly, as well as investment platforms that seed new hedge fund businesses and create alternative solutions through daily liquidity products. The company was founded by Stephen Allen Schwarzman in 1985 and is headquartered in New York, NY.

Blackstone Inc

Blackstone is trending as investors weigh the potential impact of a proposed federal ban on institutional investors purchasing single-family homes, which has triggered volatility in stocks linked to the housing sector. While the community is actively debating the legislative viability and localized market effects of this policy, many shareholders remain focused on the firm's broader diversification into AI infrastructure and energy as long-term catalysts for growth.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently trending as investors debate the stock's valuation amid significant technical pressure and conflicting analyst price targets, while the community intensely monitors its support levels ahead of upcoming earnings. Market participants are actively comparing Arms long-term potential in AI and physical infrastructure against recent bearish sentiment and price volatility.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing investor attention as it shows relative resilience and positive momentum, with the community actively debating whether its technical upgrades and transaction volume trends will lead to a significant price breakout. Investors are closely monitoring its performance against Bitcoin and other major altcoins, with many expressing long-term optimism for its utility and future market valuation.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is trending following the announcement that activist investor Elliott Investment Management has taken a 10% stake in the company to push for significant board and operational changes. Shareholders are actively debating whether this intervention will finally force a turnaround for the long-struggling operator, with many closely watching for potential leadership shifts or a future buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

REGENXBIO (NASDAQ:RGNX) Insider Sells 5,124 Shares

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) insider Steve Pakola sold 5,124 shares of the company's stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of...

REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 5,124 Shares

REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) insider Steve Pakola sold 5,124 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of...

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST PR Newswire NEW...

<ul class="summary-bullets"><li>The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted.</li><li>It added that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.&nbsp;</li><li>Sarepta Therapeutics’s FDA-approved DMD gene therapy Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li></ul>REGENXBIO Inc. (RGNX) on Wednesday announced positive interim data from the company’s early-to-mid stage trial of its gene therapy for Duchenne muscular dystrophy.The investigational gene therapy RGX-202 demonstrated evidence of positively changing disease trajectory for the disease in a few patients enrolled in the trial. It further exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted, while adding that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.Sarepta Therapeutics’s (SRPT) FDA-approved DMD gene therapy, Elevidys, came under scrutiny last year over concerns of acute liver failure and associated patient deaths. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic muscle disease affecting mostly boys.<h2 class="st-heading-2">Application Timeline</h2>REGENXBIO now expects to share topline data from the trial in early second quarter and request a meeting with the FDA in mid-2026, ahead of filing an application seeking approval for the gene therapy.In the meantime, the company will continue to enroll participants for its confirmatory trial, which is expected to have about 30 participants. The company said on Wednesday that it expects to have the majority of the trial enrolled at the time of the application submission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RGNX stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has gained nearly 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-makes-first-steps-towards-faa-certification-of-aircraft/cZdrOkARIBb">Joby Aviation Makes First Steps Towards FAA Certification Of Aircraft</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study 

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 

Equity

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 


Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals

Regenxbio releases new Duchenne trial data showing improved motor function and stable heart measures in early-stage patients.read more...

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 PR...

RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds...

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY...

Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class Action - RGNX

Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class Action - RGNX Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky...

RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP

Levi & Korsinsky, LLP examines the adequacy of REGENXBIO, Inc.'s (NASDAQ: RGNX) risk disclosures to investors during the period between February 9, 2022 and January 27, 2026. Find out if you qualify...

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Current Price	$8.57
Prev Close	$9.08
Open	$9.08
Dividend Yield	0.00%
50-Day Moving Average	$11.13
Beta	1.64
Avg. Volume	931,576.48
PE Ratio	-2.28

52-Week High	$16.19
52-Week Low	$5.04
Market Capitalization	$468.65M
EPS (Annual)	-$3.76
Price to Book	4.25
Revenue Per Employee	$459,409.70

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGNX News

RGNXRegenxbio Inc